Sara Small, MD, PhD

Publications

Small S, Oh T, Platanias LC. Role of biomarkers in the management of acute myeloid leukemia. Int J Mol Sci. 2022: 23(23):14543.

Small S, Tang E, Ragland R, Ruzankina Y, Schoppy D, Glineburg M, Ustelenca Z, Powell D, Simpkins F, Johnson F, and Brown E. Induction of Interleukin-19 through JNK and cGAS-STING modulates DNA-damage-induced cytokine expression. Sci Signal. 2021 Dec. 

Small S, Numan Y, and Platanias LC. 2021. Innate immune mechanisms and immunotherapy in myeloid malignancies. Biomedicines. 2021 Nov;9(11):1631.

Small S, Altman JK, and Platanias LC. Interferon maintenance for prevention of relapse in favorable risk AML? Leuk Lymphoma. 2021 Dec;62(12):2818-2819. 

Small S and Ma S. Frontline treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): targeted therapy versus chemoimmunotherapy. Curr Hematol Malig Rep. 2021 Aug;16(4):325-335. 

Mina A, Small S, and Platanias LC. 2021. Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections. Leuk Lymphoma. 2021 Jun;62(6):1284-1286.

Small S, Barnea Slonim L, Williams C, and Karmali R. B cell lymphomas of the GI tract. Curr Gastroenterol Rep. 2021 May;23(7):9. 

Small S, Keerthivasan G, Huang Z, Gurbuxani S, and Crispino JD. Overexpression of Survivin Initiates Hematologic Malignancies in Vivo. Leukemia. 2010 Nov;24(11):1920–1926.

Keerthivasan G, Small S, Liu H, Wickrema A, and Crispino JD. Vesicle Trafficking Plays a Novel Role in Erythroblast Enucleation. Blood. 2010 Oct;116(17):3331–3340.

Wen Q, Leung C, Huang Z, Small S, Reddi AL, Licht JD, and Crispino JD. Survivin Is Not Required for the Endomitotic Cell Cycle of Megakaryocytes. Blood. 2009;114(1):153–156.

Baldwin BR, Li L, Tse K-F, Small S, Collector M, Whartenby KA, Sharkis SJ, Racke F, Huso D, and Small D. Transgenic Mice Expressing Tel-FLT3, a Constitutively Activated Form of FLT3, Develop Myeloproliferative Disease. Leukemia. 2007 Apr;21(4):764–771.